illumiSonics Featured in BioTuesdays: Expanding the Limits of Tissue Imaging with a Single Scan

May 19, 2026 — illumiSonics has been featured in BioTuesdays in an article highlighting the company’s proprietary multi-laser imaging technology, MLI®, and its potential to transform tissue imaging across pathology, surgical imaging, and ophthalmology.

The article profiles illumiSonics’ mission to generate multiple diagnostic outputs from a single, label-free scan, helping simplify workflows, preserving scarce tissue, and unlocking new biological insights.

“Our broader ambition is to reshape how biological data is captured and used,” said John Mackey, MD, FRCPC, FCAHS, CEO of illumiSonics, in the BioTuesdays feature.

MLI® captures rich tissue information without staining or physical contact, combining light scattering, hyperspectral autofluorescence, and illumiSonics’ proprietary absorption-based signal. This creates an eight-dimensional dataset that can support applications such as virtual H&E, virtual immunohistochemistry, tumor margin assessment, and tissue-based biomarker analysis.

The BioTuesdays feature also highlights illumiSonics’ near-term commercial focus, including its Advanced Imaging Device for pathology, Surgical Imaging Device for Mohs surgery, and Retinal Imaging Device for Ophthalmology

Read the full article here:https://biotuesdays.com/2026/05/19/illumisonics-expanding-the-limits-of-tissue-imaging-with-a-single-scan/

About illumiSonics Inc.

illumiSonics Inc. is a Waterloo, Ontario based company that has developed the MLI® (Multi-Laser Imaging) platform: a transformative imaging device for life science research, digital pathology, fresh tissue diagnostics and eye imaging. MLI® is the most advanced optical absorption imaging device to date. It captures optical absorption from radiative contrast (e.g., autofluorescence), non-radiative relaxation (e.g., temperature, pressure) and scattering channels (indirect optical absorption measurement) simultaneously without contact with the tissue. The ability to generate multiple diagnoses from a single tissue sample and eliminate the need for staining addresses an unmet medical need that has the potential to save lives and reduce costs. For more information, visit www.illumisonics.com.